BO
NAVB

BRR OpCo’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

BRR OpCo’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-838
Closed -$2K – 212
2019
Q1 		$2K Buy
838
+200
+31% +$590 ﹤0.01% 171
2018
Q4 		$1K Hold
638
– – ﹤0.01% 109
2018
Q3 		$3K Buy
+638
New +$2.42K ﹤0.01% 111
2014
Q3 		– Sell
-2,385
Closed -$71K – 115
2014
Q2 		$71K Sell
2,385
-250
-9% -$8.09K 0.03% 104
2014
Q1 		$97K Hold
2,635
– – 0.04% 93
2013
Q4 		$109K Buy
+2,635
New +$103K 0.05% 94

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BRR OpCo's NAVB Position: Q2 2019 in Review

BRR OpCo sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2019, closing a stake of 838 shares — an estimated $2K sold.

BRR OpCo first reported a position in NAVB in Q4 2013 and held it in 6 quarters. The position peaked at $109K in Q4 2013. 27 funds tracked by Wall St. Rank hold NAVB as of Q2 2019.

  • BRR OpCo reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2019 after selling out during the quarter.
  • BRR OpCo sold 838 Navidea Biopharmaceuticals Inc. shares in Q2 2019, an estimated $2K.
  • BRR OpCo first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2013 and held it in 6 quarters.
  • BRR OpCo's Navidea Biopharmaceuticals Inc. position peaked at $109K in Q4 2013.
  • 27 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2019.

Based on BRR OpCo's 13F filing for Q2 2019, filed 14 Aug 2019.